Ramucirumab Not Yet Recruiting Phase 2 Trials for Non-Small Cell Lung Carcinoma (NSCLC) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03527108Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC